お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
819225

大腸癌治療:世界市場

Colorectal Cancer Therapeutics: Global Markets

出版日: | 発行: BCC Research | ページ情報: 英文 124 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
大腸癌治療:世界市場
出版日: 2019年03月29日
発行: BCC Research
ページ情報: 英文 124 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の大腸癌治療市場は2018年の137億米ドルからCAGR6.1%で拡大し、2023年までに185億米ドルに達すると予測されています。

当レポートでは、世界の大腸癌治療市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 イントロダクション

第2章 サマリーとハイライト

第3章 市場概要と生物学

  • イントロダクション
  • 市場の定義と概要
  • 発症率
  • 大腸癌の病期
  • 病因
  • 病態生理学
  • リスクファクター
  • 症状
  • 転移
  • 診断
  • 予後
  • ブロックバスター薬
  • エンドユーザー

第4章 市場動向

  • 市場促進因子
  • 市場阻害因子

第5章 パイプライン分析

  • 研究開発概要
  • 新製品開発
  • 市場への影響

第6章 治療別市場

  • 市場規模と予測
  • 化学療法
  • 免疫療法
  • 標的療法
  • 従来の治療法

第7章 地域別市場

  • イントロダクション
  • 市場規模と予測
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第8章 法規制と償還構造

第9章 競合環境と主な発展

第8章 検査タイプ別市場

第10章 企業プロファイル

第11章 付録

図表

List of Tables

  • Summary Table: Global Colorectal Cancer Therapeutics Market, by Treatment Type, Through 2023
    • Table 1: U.S. Colorectal Cancer Incidence in Males and Females, 2017
    • Table 2: Stage II and Substages of Colorectal Cancer
    • Table 3: Stage III and Substages of Colorectal Cancer
    • Table 4: Stage IV and Substages of Colorectal Cancer
    • Table 5: Treatment Options for Stage IV and Recurrent Colon Cancer
    • Table 6: Avastin Drug Details
    • Table 7: Opdivo Drug Details
    • Table 8: Cetuximab (Erbitux) Drug Details
    • Table 9: Global Trends in Population Growth of People Aged 60 Years and Older, 1980-2020
    • Table 10: Colorectal Cancer Phase I Clinical Trials, October 2018
    • Table 11: Colorectal Cancer Phase II Clinical Trials, October 2018
    • Table 12: Colorectal Cancer Phase III Clinical Trials, October 2018
    • Table 13: Global Market for Colorectal Cancer Therapeutics, by Treatment Type, Through 2023
    • Table 14: Global Colorectal Cancer Chemotherapy Market, by Region, Through 2023
    • Table 15: Global Colorectal Cancer Immunotherapy Market, by Region, Through 2023
    • Table 16: FDA Approved Therapeutic Monoclonal Antibodies used to Treat Cancer, 1997-2017
    • Table 17: Approved Tyrosine Kinase Inhibitors (TKIs) Used to Treat Cancer
    • Table 18: Global Colorectal Cancer Targeted Therapy Market, by Region, Through 2023
    • Table 19: Global Colorectal Cancer Therapeutics Market, by Region, Through 2023
    • Table 20: North American Colorectal Cancer Therapeutics Market, by Treatment Type, Through 2023
    • Table 21: North American Colorectal Cancer Therapeutics Market, by Country, Through 2023
    • Table 22: U.S. Colorectal Cancer Incidence in Males and Females, by Cancer Site, 2017
    • Table 23: Canadian Colorectal Cancer Statistics, 2017
    • Table 24: Canadian Market Statistics
    • Table 25: Mexican Market Statistics
    • Table 26: European Colorectal Cancer Therapeutics Market, by Treatment Type, Through 2023
    • Table 27: European Colorectal Cancer Therapeutics Market, by Country, Through 2023
    • Table 28: Asia-Pacific Colorectal Cancer Therapeutics Market, by Treatment Type, Through 2023
    • Table 29: Asia-Pacific Colorectal Cancer Therapeutics Market, by Country, Through 2023
    • Table 30: Japanese Market Statistics
    • Table 31: Indian Market Statistics
    • Table 32: Chinese Market Statistics
    • Table 33: Rest of World Colorectal Cancer Therapeutics Market, by Treatment Type, Through 2023
    • Table 34: Global Colorectal Cancer Therapeutics Market, by Leading Players, 2017
    • Table 35: Amgen: Company Financials, 2015-2017
    • Table 36: AstraZeneca Plc: Company Net Revenue, 2015-2017
    • Table 37: AstraZeneca Plc: Company Financials, by Therapeutic Product Group, 2015-2017
    • Table 38: Bristol-Myers Squibb: Revenue Details, by Region, 2015-2017
    • Table 39: Bristol-Myers Squibb: Oncology Product Sales, 2015-2017
    • Table 40: Eli Lilly and Co.: Net Revenue, by Segment, 2015-2017
    • Table 41: Eli Lilly and Co.: Selected Product Sales, 2016 and 2017
    • Table 42: F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, 2015-2017
    • Table 43: F Hoffman-La Roche Ltd.: Pharmaceutical Division Oncology Product Sales, 2015-2017
    • Table 44: GlaxoSmithKline: Oncology Product Pipeline
    • Table 45: Johnson & Johnson: Company Financials, by Segment, 2015-2017
    • Table 46: Johnson & Johnson: Pharmaceutical Therapeutic Area Product Sales, 2015-2017
    • Table 47: Johnson & Johnson: Oncology Product Sales, 2015-2017
    • Table 48: Merck & Co., Inc.: Therapeutic Area Product Sales, 2015-2017
    • Table 49: Merck & Co., Inc.: Oncology Product Sales, 2015-2017
    • Table 50: Novartis AG: Company Financials, by Business Segment, 2015-2017
    • Table 51: Pfizer, Inc.: Company Financials, 2015-2017
    • Table 52: Pfizer, Inc.: Innovative Health (IH) Division Financials, 2015-2017
    • Table 53: Pfizer, Inc.: Innovative Health (IH) Division Oncology Product Sales, 2015-2017
    • Table 54: Sanofi S.A.: Company Financials, 2015-2017
    • Table 55: Sanofi S.A.: Oncology Product Sales, 2015-2017
    • Table 56: Acronyms Used in Colorectal Cancer Therapeutics

List of Figures

  • Summary Figure: Global Colorectal Cancer Therapeutics Market, by Treatment Type, 2017-2023
    • Figure 1: Age-Standardized(W) Incidence Rate of Colon Cancer in Males and Females, by Region, 2018
    • Figure 2: Age-Standardized(W) Incidence Rate of Rectum Cancer in Males and Females, by Region, 2018
    • Figure 3: Five-Year Survival Rates, by Colorectal Cancer Location
    • Figure 4: North American Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 5: U.S. Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 6: Canadian Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 7: Mexican Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 8: European Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 9: German Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 10: Age-Standardized Cancer Incidence Rates of Colorectal Cancer in Males and Females, by English Regions, 2016
    • Figure 11: U.K. Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 12: French Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 13: Italian Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 14: Spanish Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 15: Rest of European Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 16: Asia-Pacific Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 17: Japanese Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 18: Indian Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 19: Chinese Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 20: Rest of Asia-Pacific Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 21: Rest of World Colorectal Cancer Therapeutics Market, 2017-2023
    • Figure 22: Federal and Inter-Provincial Approval System for Cancer Drugs in Canada
    • Figure 23: Global Colorectal Cancer Therapeutics Market Share, by Leading Players, 2017
目次
Product Code: PHM211A

Report Highlights:

The global colorectal cancer therapeutics market should reach $18.5 billion by 2023 from $13.7 billion in 2018 at a compound annual growth rate (CAGR) of 6.1% for the period 2018 to 2023.

Chemotherapy as a segment of the global colorectal cancer therapeutics market is expected to grow from $11.2 billion in 2018 to $14.8 billion in 2023 at a CAGR of 5.8% for the period 2018 to 2023.

Targeted therapy as a segment of the global colorectal cancer therapeutics market is expected to grow from $1.1 billion in 2018 to $1.6 billion in 2023 at a CAGR of 8.1% for the period 2018 to 2023.

Report Scope:

This report is a business analysis that examines market trends for colorectal cancer therapeutics. The report includes sections on the following topics -

  • Current prevalence of colorectal cancer, trend analysis and factors influencing future incidence.
  • Market analysis by treatment type, including annual incidence and trend analysis.
  • Risk factors and other drivers that may impact the future incidence of colorectal cancer.
  • Review of the major market opportunities by identifying specific high-growth and emerging market opportunities.
  • Market share and information on key market players.
  • Analysis and forecast of the revenues for colorectal cancer treatment for the global market, major market subsegments subdivided by geographic region and further, by selected country.
  • Detailed review of the current products, their indications for all identified market segments.
  • Profile of the individual market subsegments within the major market segments analyzed and the distinguishing features of each of the market subsegments.

This report captures colorectal cancer therapeutics market revenue for different regions by treatment type, i.e., chemotherapy, targeted therapy and immunotherapy used for treating the disease. A detailed colorectal cancer therapeutics market analysis covers the regions of North America, Europe, Asia-Pacific, and Rest of World.

Market values are provided using 2017 as base year, 2018 as estimated year, and 2023 as forecasted year. Estimated values used are based on manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

  • 39 data tables and 18 additional tables
  • Detailed overview of the colorectal cancer (CRC) therapeutics and corresponding global markets
  • Country specific data and analysis for France, Germany, Italy, U.K., Spain, Russia, India, China, Japan, United States, Canada, Middle East and Africa
  • Evaluation of market dynamics with a focus on increasing prevalence of colorectal cancer cases, technological advancements in radiology and chemotherapy, and increasing cancer prevention initiatives
  • Coverage of some of the significant CRC tests including CT colonography, double-contrast barium enema, and biopsy test and their usability study and future growth potential
  • A look into regulatory environment, new products launces and technological advancements, and current strategies within the market
  • Company profiles of major manufacturers and suppliers of CRC therapeutic drugs, including Abbott Laboratories, Bayer Healthcare, GlaxoSmithKline, Merck & Co. Inc., Pfizer, Inc. and Sanofi S.A.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Overview and Biology

  • Introduction
  • Market Definition and Overview
  • Incidence
  • Stages of Colorectal Cancer
    • Stage 0
    • Stage I
    • Stage II
    • Stage III
    • Stage IV
    • Standard Treatment Options for Stage IV and Recurrent Colon Cancer
    • Epidemiology of Colorectal Cancer
  • Etiology
    • Genetic Factors
    • Environmental Factors
  • Pathophysiology
  • Risk Factors
    • Inherited Syndromes
  • Symptoms
  • Metastasis
  • Diagnosis
    • Colonoscopy
    • Biopsy
    • Laboratory Tests
    • CT Scan
    • Magnetic Resonance Imaging (MRI)
    • Ultrasound
    • Others
  • Prognosis
  • Blockbuster Drugs
    • Avastin
    • Opdivo
    • Cetuximab (Erbitux)
  • End-Users
    • Hospitals
    • Cancer Research Laboratories
    • Primary Healthcare and Community Health Centers
    • Others

Chapter 4: Colorectal Cancer Market Dynamics

  • Market Drivers
    • Increasing Cancer Prevalence Rates
    • Increasing Geriatric Population
    • Outreach Programs Raise Cancer Awareness
    • Cancer and Treatment Technologies
    • Increasing Adoption of Combination and Targeted Therapies
  • Market Restraints
    • Drug Patent Expiries and Generic Drugs Emergence
    • High Costs of The Screening Associated with The Drugs
    • Lack of Awareness in Underdeveloped Countries

Chapter 5: Pipeline Analysis

  • Research and Development Overview
  • New Product Development
    • Phase I Clinical Trials
    • Phase II Clinical Trial
    • Phase III Clinical Trials
  • Impact on Market

Chapter 6: Global Colorectal Cancer Therapeutics Market Breakdown by Treatment Type

  • Market Size and Forecast
  • Chemotherapy
    • Overview
    • Neoadjuvant Chemotherapy
    • Adjuvant Chemotherapy
    • Systemic Chemotherapy
    • Regional Chemotherapy
    • First-Line Chemotherapy and Targeted Therapy
    • Side Effects
    • Second-Line Chemotherapy
    • Treatment of Liver Metastasis
    • Market Size and Forecast
  • Immunotherapy
    • Overview
    • Side Effects
    • Market Size and Forecast
  • Targeted Therapy
    • Overview
    • Targeted Chemotherapy Agents
    • Monoclonal Antibody Therapy
    • Tyrosine Kinase Inhibitors (TKIs)
    • Side Effects
    • Market Size and Forecast
  • Conventional Treatment Options
    • Surgery

Chapter 7: Global Colorectal Cancer Therapeutics Market Breakdown by Region

  • Introduction
  • Market Size and Forecast
  • North America
    • Market Size and Forecast
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Market Drivers
    • Market Restraints
    • Market Size and Forecast
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Market Size and Forecast
    • Market Drivers
    • Market Restraints
    • Japan
    • India
    • China
    • Rest of Asia-Pacific
  • Rest of World
    • Market Size and Forecast

Chapter 8: Regulatory and Reimbursement Structure

  • Overview of Regulations
    • United States
    • Canada
    • Europe
    • Japan
    • China
  • Overview of Pricing and Reimbursement
    • United States
    • Europe
    • Japan

Chapter 9: Competitive Landscape and Key Developments

  • Overview
  • Bristol-Meyers Squibb
  • Roche
  • Key Developments, 2017-2019
    • Mergers and Acquisitions
    • New Product Launch
    • Agreement, Collaboration and Partnerships

Chapter 10: Company Profiles

  • ABBVIE
  • ABBOTT LABORATORIES
  • AMGEN
  • ASTRAZENECA PLC
  • BAYER HEALTHCARE
  • BRISTOL-MYERS SQUIBB
  • ELI LILLY AND CO.
  • F HOFFMAN-LA ROCHE LTD.
  • GLAXOSMITHKLINE
  • JOHNSON & JOHNSON
  • MERCK & CO. INC.
  • NOVARTIS AG
  • PFIZER, INC.
  • SANOFI S.A.
  • TAKEDA PHARMACEUTICALS

Chapter 11: Appendix

  • Acronyms
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.